GLP-1 drugs

A new study suggests that people who discontinue GLP-1 medications, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings add to ongoing debate about how long patients should stay on these widely used weight-loss and diabetes drugs, and whether the cardiovascular benefits persist after stopping treatment.

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.

An obesity medicine doctor is addressing the growing trend of taking small, lower-than-prescribed doses of Ozempic, the weight-loss and diabetes drug semaglutide. The expert explains the potential risks of adjusting doses without medical guidance, including reduced effectiveness and side effects, while noting the limited circumstances where a low dose may genuinely make sense for some patients.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are reshaping sleep medicine, with clinicians reporting improved sleep apnea symptoms in patients losing significant weight and drugmakers seeking apnea indications. Sleep specialists are debating whether medication could reduce reliance on CPAP machines, while researchers caution that long-term effects on sleep disorders remain largely unstudied.

A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.

Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

New Zealand dairy giant Fonterra is moving to serve the nutritional needs of people taking weight-loss medications such as GLP-1 drugs, which reduce appetite and can leave users short of protein and key nutrients. The company is positioning high-protein dairy products to fill that gap, tapping into one of the fastest-growing trends in global food and health.

Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.